Paclitaxel Lipid Suspension for Platinum-Resistant Ovarian Cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new form of paclitaxel (a chemotherapy drug) in a lipid suspension for people with ovarian cancer that no longer responds to platinum-based chemo. The goal is to see if this drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
- Your cancer is resistant or refractory to platinum-based chemotherapy (progressed within 6 months of last platinum treatment).
- You have at least one measurable tumor on imaging and are well enough to carry out daily activities (ECOG 0 or 1).
- You haven't already received paclitaxel in the platinum-resistant setting (but you may have had it earlier).
- You are not pregnant or breastfeeding, and willing to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
This trial tests a new targeted therapy called DT2216 combined with the chemotherapy paclitaxel for people with ovarian cancer that is resistant to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests if adding losartan, a blood pressure medicine, to the chemotherapy drug paclitaxel can help people with ovarian cancer that has stopped responding to platinum-based treatments. It is for those whose cancer has returned within 6 months of platinum therapy or did not respond at all.
This trial tests a new drug called IBI354 against standard chemotherapy for people with ovarian, primary peritoneal, or fallopian tube cancer that stopped responding to platinum-based treatments. It aims to see if the new drug works better and has fewer side effects.
This study tests a new way of giving the chemotherapy drug paclitaxel directly into the belly cavity as a spray during a short surgery (PIPAC) for women with ovarian cancer that is no longer responding to standard platinum-based chemo. It aims to see if this treatment is safe, tolerable, and effective.
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Hear when a new Platinum-Resistant Primary Peritoneal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.